SANA
$3.22
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including...
Recent News
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index gaining 0.2% an
Sector Update: Health Care Stocks Advance Friday Afternoon
Health care stocks rose Friday afternoon, with the NYSE Health Care Index increasing 0.3% and the St
Sana: Q4 Earnings Snapshot
SEATTLE (AP) — Sana Biotechnology Inc. SANA) on Tuesday reported a loss of $58.8 million in its fourth quarter. The Seattle-based company said it had a loss of 21 cents per share.
Sana Biotechnology, Inc. (SANA): A Bull Case Theory
We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.’s share was trading at $4.00 as of February 9th. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. SANA has emerged as a […]